Valine

Valine

SCHEMBL41225

CC(C)[C@H](N)C(=O)O.CC(C)[C@H](N)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 1.00
SLC1A3 P43003 2/20 0.48
SLC1A2 P43004 2/20 0.48
SLC1A1 P43005 2/20 0.48
TP53 P04637 1/20 0.44
LAP3 P28838 1/20 0.41
DPP4 P27487 1/20 0.41
FAP Q12884 1/20 0.41
DPP8 Q6V1X1 1/20 0.41
DPP9 Q86TI2 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
USP2 O75604 1/20 0.39
SLCO1B1 Q9Y6L6 1/20 0.39
GABRP O00591 4/20 0.38
GABRD O14764 4/20 0.38
GABRA1 P14867 4/20 0.38
GABRB1 P18505 4/20 0.38
GABRG2 P18507 4/20 0.38
GABRB3 P28472 4/20 0.38
GABRA5 P31644 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL29523401 1.00
Valine SCHEMBL1813972 1.00 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1TP53
Valine SCHEMBL29828716 1.00
Valine SCHEMBL2785563 1.00 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1TP53
Valine SCHEMBL43678 1.00
Valine SCHEMBL8515 1.00
Valine SCHEMBL31618928 1.00
Valine SCHEMBL288203 1.00 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1TP53
Valine SCHEMBL8516 1.00
Valine SCHEMBL29622105 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1694 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144858-A1 TRUNCATED RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND USE THEREOF XIAMEN UNIVERSITY (CN) 2026-05-28 US claimed
US-20250382386-A1 ANTI-ALK-1 ANTIBODY AND USE THEREOF KINTOR PHARMACEUTICAL (GUANGDONG) CO., LTD (CN) 2025-12-18 US claimed
EP-4653466-A1 ANTI-ALK-1 ANTIBODY AND USE THEREOF KINTOR PHARMACEUTICAL (GUANGDONG) CO., LTD (CN) 2025-11-26 EP claimed
EP-4606823-A1 SYNTHETIC T CELL RECEPTOR ANTIGEN RECEPTOR SPECIFICALLY BINDING TO LILRB4 AND USE THEREOF Bristar Immunotech Limited (CN) 2025-08-27 EP claimed
EP-4588942-A1 TRUNCATED RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND USE THEREOF Xiamen University (CN) 2025-07-23 EP claimed
EP-3655529-B1 NEW MUTATED PTE ENZYMES LA FOND MEDITERRANEE INFECTION (FR) 2025-06-25 EP claimed
CN-120129690-A Dual receptor targeted radioligands and uses thereof 辐联科技香港有限公司 2025-06-10 CN claimed
CN-120026014-A Threonine aldolase mutant with improved enzyme activity and application thereof in L-serine production 中国科学院天津工业生物技术研究所 2025-05-23 CN claimed
CN-119816525-A Micelle composed of amphiphilic peptide and antigen carrier nanoparticle using micelle 润泰佰有限公司 2025-04-11 CN claimed
CN-119639715-A Nicotinamide mononucleotide adenyltransferase mutant and application thereof 浙江工业大学 2025-03-18 CN claimed
US-8372618-B2 Mutated hyperthermophilic phosphotriesterases and their uses UNIVERSITE HENRI POINCARE NANCY 1 (FR) 2013-02-12 US claimed
EP-2217619-B1 CYCLIC, CYSTEIN-FREE PROTEIN APEPTICO FORSCHUNG & ENTWICKLUNG GMBH (AT) 2012-11-07 EP claimed
US-20110105414-A1 CYCLIC, CYSTEIN-FREE PROTEIN APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) 2011-05-05 US claimed
US-20100333221-A1 MUTATED HYPERTHERMOPHILIC PHOSPHOTRIESTERASES AND USES THEREOF UNIVERSITE HENRI POINCARE NANCY 1 (FR) 2010-12-30 US claimed
EP-2142644-A2 MUTATED HYPERTHERMOPHILIC PHOSPHOTRIESTERASES AND USES THEREOF Université Henri Poincaré - Nancy 1 (FR) 2010-01-13 EP claimed
WO-2008145865-A2 MUTATED HYPERTHERMOPHILIC PHOSPHOTRIESTERASES AND USES THEREOF UNIVERSITE HENRI POINCARE NANCY 1 (FR) 2008-12-04 WO claimed
US-20070196884-A1 Method For The Detection Of Coliforms And In Particular Escherichia Coli ISRIM S. CONS. A.R.L. (IT) 2007-08-23 US claimed
EP-1649043-A1 METHOD FOR THE DETECTION OF COLIFORMS AND IN PARTICULAR ESCHERICHIA COLI Isrim S.C.a.r.l. (IT) 2006-04-26 EP claimed
US-20050220812-A1 Screening process SECRETARY OF STATE FOR DEFENCE, THE (GB) 2005-10-06 US claimed
WO-2005012555-A1 METHOD FOR THE DETECTION OF COLIFORMS AND IN PARTICULAR ESCHERICHIA COLI ISRIM S. CONS. A.R.L. (IT) 2005-02-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144858-A1 TRUNCATED RESPIRATORY SYNCYTIAL VIRUS F PROTEIN AND USE THEREOF FURIN, UPF1, SARS1 SLC7A5 2307/4885SLC1A3 3077/4885SLC1A2 4387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.